MG 56Alternative Names: MG56-I; MG56-II; MG56-III; MG56-IV; MG56-V; MG56-VI; MG56-VII; MG56-VIII; Pollen allergen extracts - Inmunotek
Latest Information Update: 31 Dec 2015
At a glance
- Originator Inmunotek
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 27 Nov 2015 Phase-II clinical trials in Allergic rhinitis and Allergic rhinoconjunctivitis (In adolescents, In adults) in Spain (SC and Sublingual) (NCT02654223; EudraCT2014-005471-88)